These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 31676332)

  • 41. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
    Kim MK; Kim DM
    J Diabetes Investig; 2021 Jun; 12(6):914-916. PubMed ID: 33759351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.
    DeFronzo RA
    Diabetes Obes Metab; 2017 Oct; 19(10):1353-1362. PubMed ID: 28432726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.
    Yagyu H; Shimano H
    J Diabetes Investig; 2022 Sep; 13(9):1472-1488. PubMed ID: 35638331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.
    Diallo A; Carlos-Bolumbu M; Renard PE; Galtier F
    Diabetes Obes Metab; 2023 Jan; 25(1):166-176. PubMed ID: 36057779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New Antidiabetes Medications and Their Cardiovascular and Renal Benefits.
    Ferro EG; Elshazly MB; Bhatt DL
    Cardiol Clin; 2021 Aug; 39(3):335-351. PubMed ID: 34247748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Glucose-Lowering Agents for Diabetic Kidney Disease.
    de Vos LC; Hettige TS; Cooper ME
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications.
    Liu H; Zhang JT; Xin SH; Ren WN; Lu QK
    Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2332-2340. PubMed ID: 37013752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
    Cattadori G; Pantanetti P; Ambrosio G
    Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?
    Lee B; Holstein-Rathlou NH; Sosnovtseva O; Sørensen CM
    Am J Physiol Cell Physiol; 2023 Jul; 325(1):C243-C256. PubMed ID: 37273240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.
    Brockmeyer M; Parco C; Vargas KG; Westenfeld R; Jung C; Kelm M; Roden M; Akbulut C; Schlesinger S; Wolff G; Kuss O
    J Nephrol; 2024 Mar; 37(2):309-321. PubMed ID: 38236473
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.
    Trevella P; Ekinci EI; MacIsaac RJ
    Nephrology (Carlton); 2024 Aug; 29(8):457-469. PubMed ID: 39030739
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy with kidney protective therapies: optimizing the benefits?
    Kotwal S; Perkovic E; Perkovic V
    Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):136-143. PubMed ID: 37767945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
    Shah N; Perkovic V; Kotwal S
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.